Figure 7.

(a, b) Representative recordings of cardiomyocyte shortening. Expanded traces show contractility at the 2 and 4 min time points. (a) 3 nM ATXII produces contractile dysfunction. (b) Contractile dysfunction occurs later and to a lesser extent in the presence of both 3 nM ATXII and 100 μM resveratrol. (c) 3 nM ATXII produces contractile dysfunction; with application of 100 μM resveratrol during the first 5 min of ATXII treatment, contractile dysfunction is significantly delayed; ^*P<0.001. (d) 3 nM ATXII produces contractile dysfunction as measured by the occurrence of abnormal contractions; with the addition of 100 μM resveratrol, a significantly smaller incidence of abnormal contractions is observed; ^*P<0.001 (n=7 in all groups).